01
Its CFTR-modulator franchise - anchored by Trikafta/Kaftrio and the next-generation once-daily Alyftrek (vanzacaftor/tezacaftor/deutivacaftor, FDA-approved December 2024) - treats the large majority of the addressable CF population and generated the bulk of $12.0B in FY2025 revenue, with $4.0B of GAAP net income. Vertex is now deploying that cash flow to diversify well beyond CF. It commercialized Casgevy (exagamglogene autotemcel), the first CRISPR/Cas9 gene-editing therapy ever approved, for sickle cell disease and beta thalassemia, partnered with CRISPR Therapeutics. In January 2025 it launched Journavx (suzetrigine), the first genuinely new class of pain medicine in over two decades - an oral, non-opioid NaV1.8 inhibitor. Its pipeline includes zimislecel (VX-880), a stem-cell-derived islet therapy that has rendered type 1 diabetes patients insulin-independent in trials; inaxaplin for APOL1-mediated kidney disease; and povetacicept (from the $4.9B Alpine acquisition) for IgA nephropathy, with an FDA decision due November 30, 2026. On September 1, 2026 it completed the ~$10B acquisition of endocrine-disease specialist Crinetics Pharmaceuticals - its largest-ever deal - adding Palsonify (paltusotine), the first once-daily oral acromegaly drug, already launched in the US and approved in the EU, plus Phase 3 candidate atumelnant. Jasper van Grunsven joined on September 8, 2026 as EVP and Chief Pain and New Product Planning Officer to run the pain franchise and global new-product planning. Vertex pushes the envelope by turning single-gene biology into functional cures.
bostonlifesciencestimes.comUpdated Sep 8, 2026
Analysis · 5 min read · Aug 15, 2026The long view on Vertex Pharmaceuticals: strategy, technology and what to watch02
2026–2027
Target2026–2027 (at risk)
File global regulatory submissions for the stem-cell islet therapy that has produced insulin-independence - potential functional cures - in trial participants, a landmark for cell therapy. Vertex temporarily postponed completion of dosing in early 2026 pending an internal manufacturing analysis, has since completed that analysis and resumed dosing, and continues to enroll and dose patients in the Phase 1/2/3 study. In parallel, the FDA cleared an IND for VX-017, a 'type O' universal-donor islet cell therapy, and Vertex is now weighing bringing VX-017 to market at or near the same time as zimislecel rather than sequencing the two. The company says it will provide updated regulatory and commercial timelines for the whole type 1 diabetes portfolio later in 2026; no BLA/MAA has been filed for either program as of late August 2026.
2026 ongoing
Convert Trikafta patients onto the once-daily Alyftrek and expand international launches to extend the cystic fibrosis franchise. Alyftrek is now approved in the US, UK, EU (covering an addressable population of about 31,000 CF patients), Canada, Switzerland, Australia and New Zealand. Vertex signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance on July 6, 2026 following positive reimbursement recommendations from CDA-AMC and INESSS, and has secured reimbursement agreements in Scotland, Spain, Sweden, Switzerland, New Zealand, Israel and Finland, with more countries in progress. Vertex also plans global regulatory submissions to extend the label to children ages 2-5.
2H 2026
Target2H 2026 (full enrollment); interim analysis early 2027
Advance the AMPLITUDE Phase 2/3 trial of inaxaplin (VX-147), a once-daily oral therapy that could be the first treatment targeting the underlying cause of APOL1-mediated kidney disease (now expanded to include adolescents ages 10-17). Vertex has completed enrollment of the interim-analysis cohort and expects the pre-planned Week 48 interim analysis - which could support a US accelerated approval filing if positive - in late 2026 or early 2027; full study enrollment (~466 patients) remains on track to complete in the second half of 2026.
Late 2026
Having closed the ~$10B Crinetics acquisition on September 1, 2026, Vertex must integrate the Palsonify commercial business (US-launched, EU-approved April 27, 2026) and the atumelnant pipeline (Phase 3 CAH, Phase 2 Cushing's). Charles Wagner expanded his COO remit to include the integration; Jonathan Poole becomes EVP and CFO on January 1, 2027. Jasper van Grunsven started September 8, 2026 as EVP and Chief Pain and New Product Planning Officer. Updated 2026 financial guidance that includes Crinetics is due with Q3 results on November 2, 2026.
Nov 30, 2026
Await the FDA decision on povetacicept (from the Alpine acquisition) for IgA nephropathy after Phase 3 RAINIER showed a 52% reduction in proteinuria; the BLA was accepted under accelerated approval (using a priority review voucher to cut review time from ten months to six) with a PDUFA target action date of November 30, 2026. If approved, povetacicept becomes Vertex's first commercialized nephrology product.
End of 2026
TargetEnd of 2026 (DPN Phase 3 enrollment)
Broaden Journavx beyond acute pain into chronic pain. After the FDA indicated it did not see a path to a broad peripheral-neuropathic-pain label, Vertex narrowed its near-term plan to two identical, roughly 1,100-patient Phase 3 studies specifically in diabetic peripheral neuropathy (DPN) at a once-daily 70mg dose, with enrollment in both expected to complete by the end of 2026.
Jan 1, 2027
03
The European Medicines Agency said on September 18 that Vertex Pharmaceuticals (Ireland) Limited had withdrawn applications to extend Kaftrio (ivacaftor/tezacaftor/elexacaftor) and Kalydeco (ivacaftor) to children aged one year and older with cystic fibrosis, used together as a combination regimen. The notice came in the CHMP highlights from the committee's September 14-17 meeting, which listed the pair among three already-authorised medicines whose indication-extension filings were pulled. Existing EU approvals for older patients are not themselves revoked by the withdrawals.
The US Court of Appeals for the District of Columbia Circuit on September 4, 2026 affirmed a lower-court finding that Vertex's program offering fertility-preservation services to Casgevy patients violates the federal Anti-Kickback Statute. The court said the perk was remuneration meant to induce purchase of the multimillion-dollar sickle-cell gene therapy. Bloomberg Law reported the panel stopped short of affirming a separate lower-court conclusion, leaving Vertex to recast how it supports patients through Casgevy's fertility risks.
Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals on September 1, 2026, a deal worth about $10.0 billion in total equity value (roughly $8.8 billion net of acquired cash), after clearing shareholder and antitrust approvals. The deal adds the marketed acromegaly drug Palsonify (paltusotine) and pipeline candidate atumelnant, and Vertex announced an expanded executive leadership team, naming Jonathan Poole EVP and Chief Financial Officer and adding Jasper van Grunsven as EVP, Chief Pain and New Product Planning Officer, to support the new endocrine-disease business.
Crinetics Pharmaceuticals shareholders voted on August 28, 2026 to approve Vertex Pharmaceuticals' $85-per-share, roughly $10 billion cash acquisition, clearing the final outstanding condition after antitrust clearances were received in the US, Austria, Germany, and Australia. The deal, Vertex's largest ever, brings it the marketed acromegaly drug Palsonify and an endocrinology pipeline including atumelnant, with the companies now expecting the transaction to close around September 1, 2026.
A Delaware federal court ruled on August 24 that Lupin's proposed generic version of Vertex's cystic fibrosis drug Kalydeco does not infringe Vertex's patents, finding Lupin's 74% ivacaftor formulation falls outside the patents' claimed 80% concentration range. The ruling clears a path for Lupin, which already holds tentative FDA approval, to launch the first generic challenger to a Vertex CF modulator pending final FDA approval.
Sionna Therapeutics said on August 10 that its cystic fibrosis add-on candidate SION-719, designed to be paired with Vertex's Trikafta, missed the primary endpoint in its Phase 2a trial and halted the program. The failure removed one of the most closely watched competitive threats to Vertex's dominant CF franchise, and Vertex shares rose roughly 7-9% intraday on the news.
Vertex Pharmaceuticals reported Q2 2026 revenue of $3.33 billion on August 3, up 12% year over year, with net income of $1.10 billion and EPS of $4.34. The company raised full-year 2026 revenue guidance to $13.1-13.2 billion, driven partly by CASGEVY revenue growing 151% year over year to $76 million and JOURNAVX revenue roughly quadrupling to $50 million, with the two products now expected to contribute over $500 million combined for the year.
AbCellera announced July 29 a collaboration with Vertex Pharmaceuticals to discover multispecific T-cell engagers for autoimmune diseases and other conditions. AbCellera will lead early discovery on its proprietary TCE platform while Vertex funds all research and development and holds rights to develop and commercialize resulting antibodies, paying AbCellera $28 million upfront plus preclinical, development, regulatory and commercial milestone payments and tiered sales royalties.
Vertex Pharmaceuticals agreed on July 6 to acquire endocrine-disease specialist Crinetics Pharmaceuticals for $85 per share in cash, valuing the San Diego company at roughly $10 billion - Vertex's largest acquisition to date and about a 102% premium to Crinetics' prior close. The deal hands Vertex Palsonify (paltusotine), an oral once-daily drug approved in September 2025 for acromegaly, plus an endocrinology pipeline the companies say could deliver more than $5 billion in combined peak annual revenue. Approved by both boards, the transaction is expected to close in the third quarter of 2026 and become accretive to non-GAAP operating income in 2029.
The U.S. FDA on July 1 approved expanded use of Casgevy (exagamglogene autotemcel) - the world's first approved CRISPR/Cas9 gene-editing medicine, developed by Vertex Pharmaceuticals with CRISPR Therapeutics - for patients ages 2 and older with sickle cell disease or transfusion-dependent beta thalassemia, lowering the prior age floor of 12. Vertex said the expansion makes roughly 5,500 additional U.S. children newly eligible for the one-time therapy. CRISPR shares rose about 8% and Vertex about 6% on the news; CRISPR retains roughly 40% of Casgevy's economics under the partnership.
04
Vertex's flagship cystic fibrosis triple-combination CFTR modulator (elexacaftor/tezacaftor/ivacaftor), effective for roughly 90% of CF patients and the company's dominant revenue engine - now complemented by the once-daily next-generation Alyftrek.
A first-in-class oral, non-opioid pain medicine (VX-548) that selectively inhibits the NaV1.8 sodium channel to block pain signals in the peripheral nervous system before they reach the brain - the first new class of pain drug in over 20 years.
The first approved CRISPR/Cas9 gene-editing medicine (exagamglogene autotemcel), a one-time therapy for sickle cell disease and transfusion-dependent beta thalassemia, developed and commercialized with CRISPR Therapeutics.
An allogeneic, stem-cell-derived, fully differentiated islet cell therapy for type 1 diabetes designed to restore the body's own insulin production - a potential functional cure delivered as a one-time infusion.
An oral, once-daily somatostatin receptor agonist for acromegaly, acquired through the Crinetics Pharmaceuticals deal - Vertex's first marketed product outside CF, pain, and gene therapy, and the anchor of its new endocrine-disease business.
An oral pipeline candidate for endocrine disease acquired with Crinetics Pharmaceuticals, part of the endocrinology pipeline Vertex and Crinetics said could reach $5B+ in combined peak annual sales alongside Palsonify.
05
(+12% YoY); $12.0B FY2025; 2026 guidance raised to $13.1-13.2B (pre-Crinetics; Q3 update due Nov 2, 2026)
(+12% YoY); 2026 guidance raised to $13.1-13.2B (pre-Crinetics; updated guidance due with Q3 on Nov 2, 2026)
(Jun 30, 2026). The ~$8.8B net Crinetics close on Sept 1, 2026 was funded from cash plus term-loan borrowings; Vertex has not yet restated cash and will update with Q3 results on Nov 2, 2026.
$50M Q2 2026 product revenue, up 71% sequentially and more than 4x YoY; ~535,000 prescriptions filled in Q2 2026 alone, nearing 1 million cumulative prescriptions
$76M in Q2 2026, up 151% YoY and 78% sequentially; third consecutive quarter with 100+ patient initiations, with more infusions in H1 2026 than all of 2025 combined
06
Operating status
Profitable, commercial-scale
Vertex runs a dominant, high-margin cystic fibrosis franchise (US CF revenue rose 13% to $7.55B in 2025) that funds diversification into non-opioid pain, CRISPR gene therapy, type 1 diabetes cell therapy, kidney disease, and now rare endocrine disease. Q2 2026 revenue rose 12% to $3.33B with net income of $1.10B; full-year 2026 guidance of $13.1-13.2B does not yet include Crinetics, which closed September 1, 2026 for about $10.0B equity value (~$8.8B net of cash). Palsonify is already launched in the US and approved in the EU. Jasper van Grunsven started September 8, 2026 as EVP over the pain franchise and new-product planning. The nearest credible CF challenger, Sionna Therapeutics, halted its lead program after a Phase 2 failure in August 2026. Next catalysts: povetacicept PDUFA on November 30, 2026 and Q3 results on November 2, 2026.
The overwhelming majority of revenue: Trikafta/Kaftrio plus the next-generation once-daily Alyftrek. US CF revenue grew 13% to $7.55B in 2025, with further growth from ex-US Alyftrek launches and label expansions to younger patients.
Vertex's non-opioid pain medicine, generating $50M of product revenue in Q2 2026 (more than 4x YoY) as formulary access expands; about 535,000 prescriptions were filled in Q2 2026 alone, nearing 1 million cumulative fills.
The CRISPR gene-editing therapy for sickle cell disease and beta thalassemia, co-commercialized with CRISPR Therapeutics; Vertex books the product revenue (~$116M in FY2025) as authorized treatment centers scale globally.
Emerging (diabetes, kidney, and endocrine disease)
Future streams from zimislecel (type 1 diabetes), inaxaplin (APOL1-mediated kidney disease), and povetacicept (IgA nephropathy, PDUFA November 30, 2026), plus Palsonify (acromegaly) revenue now booked after the September 1, 2026 Crinetics close.
07
How past announced dates turned out.
1/1announced date hit on time
Close the ~$10B Crinetics acquisition
Target Early September 2026 · Resolved Sep 1, 2026
Vertex completed the acquisition of Crinetics Pharmaceuticals on September 1, 2026 for about $10.0 billion in total equity value (~$8.8 billion net of acquired cash), adding Palsonify (paltusotine) and atumelnant, and announced an expanded executive leadership team - Jonathan Poole as EVP and Chief Financial Officer and Jasper van Grunsven joining as EVP, Chief Pain and New Product Planning Officer - to run the new endocrine-disease business.
08
2026
Sets third-quarter results for November 2
On October 7, 2026 Vertex said it will report third-quarter 2026 financial results on Monday, November 2, 2026, after the market close, with a conference call and webcast at 4:30 p.m. ET. The US dial-in is (833) 630-2124 and the international dial-in is +1 (412) 317-0651, referenced as the Vertex Pharmaceuticals Third Quarter 2026 Earnings Call. This is the reporting date, not the sales result.
Appoints Jonathan Poole as CFO, effective January 1, 2027
On August 27, 2026 Vertex appointed Jonathan Poole, previously Senior Vice President, Finance, as Executive Vice President and Chief Financial Officer, effective January 1, 2027. Charles F. Wagner, Jr. will stop serving as Chief Financial Officer on that date and remain Executive Vice President and Chief Operating Officer. The Item 5.02 Form 8-K was filed September 1, 2026. Employment and change-of-control agreements are to be filed with the Form 10-Q for the quarter ended September 30, 2026. This is a succession date, not an immediate CFO change.
Withdraws EU filings to extend Kaftrio and Kalydeco to age one
The European Medicines Agency said on September 18, 2026 that Vertex Pharmaceuticals (Ireland) Limited had withdrawn applications to extend Kaftrio (ivacaftor/tezacaftor/elexacaftor) and Kalydeco (ivacaftor) to children aged one year and older with cystic fibrosis, used together as a combination regimen. The CHMP listed the pair among three already-authorised medicines whose indication-extension filings were pulled at its September 14-17 meeting. Existing EU approvals for older patients are not themselves revoked.
Jasper van Grunsven joins to run the pain franchise
Jasper van Grunsven, formerly senior vice president of Amgen's rare-disease portfolio, starts as Executive Vice President and Chief Pain and New Product Planning Officer on September 8, 2026, overseeing Journavx and global new-product planning as Vertex integrates Crinetics and expands beyond cystic fibrosis.
DC Circuit says Casgevy fertility perk violates anti-kickback law
On September 4, 2026 the US Court of Appeals for the District of Columbia Circuit affirmed a lower-court finding that Vertex's program offering fertility-preservation services to Casgevy patients violates the federal Anti-Kickback Statute, treating the perk as remuneration meant to induce purchase of the gene therapy. Bloomberg Law reported the panel stopped short of affirming a separate lower-court conclusion.
Completes $10B Crinetics acquisition, enters endocrine disease
Vertex completes its acquisition of Crinetics Pharmaceuticals on September 1, 2026 for about $10.0 billion in total equity value (~$8.8 billion net of acquired cash), adding the marketed acromegaly drug Palsonify (paltusotine) and pipeline candidate atumelnant. Vertex expands its executive leadership team to run the new business, naming Jonathan Poole EVP and Chief Financial Officer and adding Jasper van Grunsven as EVP, Chief Pain and New Product Planning Officer.
Loses patent case, clearing a path for generic Kalydeco
The US District Court for the District of Delaware ruled on August 24, 2026 that Lupin's proposed generic version of Vertex's cystic fibrosis drug Kalydeco (ivacaftor) does not infringe Vertex's patents. Judge Stephanos Bibas found that Lupin's formulation, containing about 74% ivacaftor, falls outside the 'about 80%' concentration range claimed in Vertex's patents, rejecting Vertex's broader interpretation of 'about.' The ruling clears a legal hurdle for Lupin, a first-to-file applicant that already holds tentative FDA approval and could gain 180 days of marketing exclusivity for the generic pending final FDA approval - the first real threat to a Vertex CF modulator's exclusivity, though Kalydeco is now an older, smaller part of the CF franchise next to Trikafta and Alyftrek.
Closest cystic fibrosis rival fails Phase 2, shares hit all-time high
Sionna Therapeutics said on August 10, 2026 that its cystic fibrosis add-on candidate SION-719 - designed to be paired with Vertex's Trikafta and the closest credible challenge to Vertex's CF franchise - missed the primary endpoint in its Phase 2a trial, and the company halted the program; Sionna's stock lost roughly 90% of its value in a day. Vertex shares rose to an all-time high on the news, underscoring how uncontested its cystic fibrosis franchise remains.
2026
Q2 2026 results beat, guidance raised
Vertex reported Q2 2026 revenue of $3.33 billion on August 3, up 12% year over year, with net income of $1.10 billion and EPS of $4.34. The company raised full-year 2026 revenue guidance to $13.1-13.2 billion, driven partly by CASGEVY revenue growing 151% year over year to $76 million and JOURNAVX revenue roughly quadrupling to $50 million. ALYFTREK, the once-daily next-generation CF modulator, surpassed $1 billion in cumulative revenue in the first half of 2026 on rapid uptake in the US, Germany, and the UK.
Partners with AbCellera on autoimmune T-cell engagers
On July 29, 2026 Vertex enters a collaboration with AbCellera to discover multispecific T-cell engagers for autoimmune diseases and other conditions. AbCellera leads early discovery on its proprietary TCE platform while Vertex funds all R&D and holds development and commercialization rights, paying AbCellera $28M upfront plus preclinical, development, regulatory and commercial milestones and tiered sales royalties.
Agrees to acquire Crinetics for ~$10B - largest deal ever
On July 6, 2026 Vertex agrees to acquire endocrine-disease specialist Crinetics Pharmaceuticals for $85 per share in cash (~$10B equity value, ~$8.8B net of cash; about a 102% premium) - its largest acquisition to date. The deal adds Palsonify (paltusotine), an oral once-daily acromegaly drug approved in September 2025, plus an endocrinology pipeline (including atumelnant) the companies say could deliver $5B+ in combined peak annual revenue. Structured as a one-step merger requiring a Crinetics shareholder vote - Crinetics filed a preliminary proxy in July 2026 - plus antitrust clearances, and funded from cash on hand plus a committed $4.5B bridge facility. Closing is expected in Q3 2026 and had not yet completed as of late July.
FDA expands Casgevy to children ages 2+
On July 1, 2026 the FDA approves expanded use of Casgevy (exa-cel) for both sickle cell disease and transfusion-dependent beta thalassemia in patients ages 2 and older - down from 12+ - making it the first gene therapy cleared for children as young as two and adding roughly 5,500 newly eligible U.S. children. Vertex and partner CRISPR Therapeutics guide Casgevy revenue to roughly triple in 2026 as authorized treatment centers scale.
Record year: $12.0B revenue, $4.0B net income
Reports FY2025 revenue of $12.0B (+9%) and GAAP net income of $4.0B, guiding to $12.95–13.1B for 2026 including $500M+ from non-CF products, and continuing a $2.0B annual share-buyback program.
2025
Zimislecel delivers functional cures in type 1 diabetes
At the June 2025 ADA meeting, Vertex reports that all 10 type 1 diabetes participants dosed with zimislecel became insulin-independent at one year with >90% time-in-range; the data are published in the New England Journal of Medicine.
Journavx (suzetrigine) - first new pain-drug class in 20+ years
On January 30, 2025 the FDA approves Journavx (suzetrigine), a first-in-class oral, non-opioid NaV1.8 inhibitor for moderate-to-severe acute pain - the first genuinely new class of pain medicine in more than two decades.
2024
Alyftrek - next-generation once-daily CF combo approved
The FDA approves Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) in December 2024, a once-daily next-in-class CFTR modulator that Vertex begins converting patients onto to extend its CF franchise.
Alpine Immune Sciences acquisition ($4.9B)
Acquires Alpine Immune Sciences for ~$4.9B, adding povetacicept (a BAFF/APRIL inhibitor) and a broader immunology and nephrology pipeline. The one-time acquired-IPR&D charge drove a temporary GAAP net loss that year.
2023
2019
Acquires Semma Therapeutics for diabetes cell therapy
Buys Semma Therapeutics for ~$950M, entering stem-cell-derived islet therapy for type 1 diabetes - the program that became zimislecel (VX-880).
Trikafta approved - the transformational triple combo
The FDA approves Trikafta (elexacaftor/tezacaftor/ivacaftor), a triple-combination modulator that is effective for roughly 90% of CF patients and becomes Vertex's revenue engine.
2015
2012
1991
1989
09
$16.2Bdisclosed across 4 rounds with a stated amount
Cumulative disclosed raise · dated rounds
IPO (NASDAQ: VRTX)
1991
Public markets; now a Nasdaq-100 and S&P 500 component
Semma Therapeutics acquisition
2019
Capital deployment (type 1 diabetes cell therapy)
ViaCyte acquisition
2022
Capital deployment (diabetes cell-therapy assets)
Alpine Immune Sciences acquisition
2024
Capital deployment (povetacicept; immunology/nephrology)
Crinetics Pharmaceuticals acquisition (completed)
2026
~$10.0B total equity value (~$8.8B net of acquired cash); $85/share cash
Capital deployment (Palsonify; endocrinology). Closed September 1, 2026
Share repurchases
2025
Self-funded from operating cash flow
